Trial reportLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2019
Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
Trial report in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Precision inflammation targeting via myeloperoxidase mediated antioxidant melanin nanomedicines for chronic inflammation therapy.Nature communications · 2026Article
- Agrimoniin ameliorates intrapulmonary angiogenesis and improves hypoxemia in hepatopulmonary syndrome via PGC-1α activation and glycolysis down-regulation.Genes & diseases · 2026Article
- Alveolar Type 2 Cell Dysfunction Is Associated with Bile Acid Alterations in Experimental Hepatopulmonary Syndrome.American journal of respiratory cell and molecular biology · 2026Article
- A Tale of Two Organs: The Liver-Lung Axis in Pulmonary Disease.Comprehensive Physiology · 2025Article
- Disruption of Hepatic Sinusoidal Homeostasis Leads to Hepatopulmonary Syndrome.Journal of cellular and molecular medicine · 2025Review
- Effects of Transjugular Intrahepatic Portosystemic Shunt on Renal and Pulmonary Function in Hepatic Decompensation with and without Hepatorenal and Hepatopulmonary Syndromes: A Review.Journal of clinical and translational hepatology · 2024Review
- The Therapeutic Effects of Baicalein on the Hepatopulmonary Syndrome in the Rat Model of Chronic Common Bile Duct Ligation.Journal of clinical and translational hepatology · 2024Article
- Serum Soluble Vascular Endothelial Growth Factor Receptor 1 as a Potential Biomarker of Hepatopulmonary Syndrome.Journal of clinical and translational hepatology · 2023Article
- Unexplained Dyspnea: Hepatopulmonary Syndrome without Cirrhosis?Annals of the American Thoracic Society · 2023Article
- Hepatopulmonary syndrome.JHEP reports : innovation in hepatology · 2022Review
- Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis.The European respiratory journal · 2022Article
- Hepatopulmonary syndrome: An update.World journal of hepatology · 2021Review
- Article
- Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation.Current hepatology reports · 2020Article
- [Diagnosis and therapeutic strategies for hepatopulmonary syndrome].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020Article
- Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease.Clinical liver disease · 2020Review
- Kidney and lung tissue modifications after BDL-induced liver injury in mice are associated with increased expression of IGFBPrP1 and activation of the NF-κB inflammation pathway.International journal of clinical and experimental pathology · 2020Article
- Pulmonary Assessment of the Liver Transplant Recipient.Journal of clinical and experimental hepatologyReview
- Pulmonary manifestations of chronic liver disease: a comprehensive review.Annals of gastroenterologyReview
Corrections and comments
- Commented on by
Authors and funding
19 authors at 8 institutions in 2 countries.
Funding
Abstract
The tyrosine kinase inhibitor sorafenib improves hepatopulmonary syndrome (HPS) in an experimental model. However, the efficacy and adverse effect profile in patients with HPS are unknown. We aimed to determine the effect of sorafenib on the alveolar-arterial oxygen gradient (AaPO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.